1. Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascularend points: effect of angiotensin-converting enzyme inhibitors andangiotensin receptor blockers. Am Heart J 2004; 148: 747–54.
2. Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensusdocument on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the EuropeanSociety of Cardiology. Eur Heart J 2004; 25: 1454–70.
3. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events inhigh-risk patients. The Heart Outcomes Prevention Evaluation StudyInvestigators. N Engl J Med 2000; 342: 145–53.
4. Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003; 21: 1599–608.
5. Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother 2005; 39: 470–80.
6. Fox KM, EURopean trial On reduction of cardiac events withPerindopril in stable coronary Artery disease Investigators. Efficacyof perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
7.Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-convert-ing-enzyme inhibition in stable coronary artery disease. N Engl JMed 2004; 351: 2058–68.
8. Halkin A, Keren G. Potential indications for angiotensin-convertingenzyme inhibitors in atherosclerotic vascular disease. Am J Med 2002; 112: 126–34.
9. Dzau VJ. Mechanism of protective effects of ACE inhibition oncoronary artery disease. Eur Heart J 1998; 19 (Suppl.): J2–J6.
10. Pepine CJ, Rouleau JL, Annis K et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the QuinaprilAnti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. JAm Coll Cardiol 2003; 42: 2049–59.
11. Ueshima K, Fukami K, Hiramori K et al. Is angiotensin-convertingenzyme inhibitor useful in a Japanese population for secondaryprevention after acute myocardial infarction? A final report of theJapanese Acute Myocardial Infarction Prospective (JAMP) study. AmHeart J 2004; 148: e8.
12. Bartels GL, van den Heuvel FM, van Veldhuisen DJ et al. Acute anti-ischemic effects of perindoprilat in men with coronary artery diseaseand their relation with left ventricular function. Am J Cardiol 1999; 83: 332–6.
13. Borghi C, Bacchelli S, Degli D et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004; 5: 1965–77.
14. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-'nverting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80–5.
15. Borghi C, Ambrosioni E, Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heartFailure in patients with anterior wall acute myocardial infarction. TheSMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Cardiol 1996; 78: 317–22.
16. Borghi C, Bacchelli S, Esposti DD et al. Effects of the administrationof an angiotensin-converting enzyme inhibitor during the acutephase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999; 12: 665–72.
17. Borghi C, Bacchelli S, Esposti DD et al. SMILE Study. Effects of theearly ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 2003; 26: 1862–8.
18. Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation-2 Working PartyDouble-blind comparison betweenzofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145: 80–7.
19. Cushman DW, Wang FL, Fung WC et al. Differentiation ofangiotensin converting enzyme (ACE) inhibitors by their selectiveinhibition of ACE in physiologically important target organs. Am JHypertens 1989; 2: 294–307.
20. Sargent CA, Sleph PG, Dzwonczyk S et al. Cardioprotection inischemic rat hearts with the SH-containing angiotensin-convertingenzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J Pharmacol Exp Ther 1993; 265: 609–18. 445.
21. Napoli C, Cicala C, D'Armiento FP et al. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-densitylipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. Gen Pharmacol 1999; 33: 467–77.
22. de Nigris F, D'Armiento FP, Somma P et al. Chronic treatmentwith sulfhydryl angiotensin-converting enzyme inhibitors reducesusceptibility of plasma LDL to in vitro oxidation, formation ofoxidation-specific epitopes in the arterial wall, and atherogen-esis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81: 107–15.
23. Cominacini L, Pasini A, Garbin U et al. Zofenopril inhibits theexpression of adhesion molecules on endothelial cells byreducing reactive oxygen species. Am J Hypertens 2002; 15: 891–5.
24. Frascarelli S, Ghelardoni S, Ronca-Testoni S et al. Cardioprotectiveeffect of zofenopril in perfused rat heart subjected to ischemia andreperfusion. J Cardiovasc Pharmacol 2004; 43: 294–9.
25. Napoli C, Sica V, de Nigris F et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction ofsystemic oxidative stress and improves the nitric oxide pathwayin patients with essential hypertension. Am Heart J 2004; 148: e5.
26. Evangelista S, Manzini S. Antioxidant and Cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitorzofenopril. J Int Med Res 2005; 33: 42–54.
27. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitorsimprove contractile function of stunned myocardium by differentmechanisms of action. Am Heart J 1991; 121: 1319–30.
28. Tamesis B, Stelken A, Byers S et al. Comparison of theasymptomatic cardiac ischemia pilot and modified asymptomaticcardiac ischemia pilot versus Bruce and Cornell exercise protocols. Am J Cardiol 1993; 72: 715–20.
29. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxistress. Eur J Pharmacol 2003; 482: 95–9.
30. Ertl G, Hu K. Anti-ischemic potential of drugs related to therenin-angiotensin system. J Cardiovasc Pharmacol 2001; 37 (Suppl. 1): S11–S20.
31. Tsikouris JP, Suarez JA, Meyerrose GE. Plasminogen activatorinhibitor-1: physiologic role, regulation, and the influence ofcommon pharmacologic agents. J Clin Pharmacol 2002; 42: 1187–99.
32. Reinhardt D, Sigusch HH, Hensse J et al. Cardiac remodelling inend-stage heart failure: upregulation of matrix metalloproteinase(MMP) irrespective of the underlying disease, and evidence for adirect inhibitory effect of ACE inhibitors on MMP. Heart 2002; 88: 525–30.
33. Buikema H, Monnink SH, Tio RA et al. Comparison of zofenopriland lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimentalheart failure. Br J Pharmacol 2000; 130: 1999–2007.
34. Pfeffer MA, Braunwald EA, Moye´ LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunc-n after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669–77.
35. Svensson P, de Faire U, Sleight P et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38: E28-E32.